We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Kills Mylan's Prilosec Antitrust Claims

Law360 (March 8, 2011, 4:01 PM EST) -- The Federal Circuit on Tuesday rejected Mylan Laboratories Inc.'s bid to revive allegations that AstraZeneca AB violated antitrust law by filing sham patent infringement suits to protect its heartburn drug Prilosec.

A three-judge panel of the U.S. Court of Appeals for the Federal Circuit upheld Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York's grant of summary judgment to AstraZeneca and dismissal of Mylan's counterclaims.

Mylan argued before the Federal Circuit on Monday that the antitrust claims shouldn't have...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.